Not available
Quote | Cogent Biosciences (NASDAQ:UMRX)
Last: | $2.35 |
---|---|
Change Percent: | 0.43% |
Open: | $2.38 |
Close: | $2.35 |
High: | $2.41 |
Low: | $2.3201 |
Volume: | 124,651 |
Last Trade Date Time: | 10/05/2020 04:45:26 am |
News | Cogent Biosciences (NASDAQ:UMRX)
CAMBRIDGE, Mass. and BOULDER, Colo., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced Andrew Robbins, Chief Executive Officer and President, wil...
Shares of left-for-dead Unum Therapeutics surged nearly 400% on its acquisition of privately held Kiq Bio and a concurrent $104.4 million capital infusion. Kiq provided Unum with one clinical candidate (PLX9486) for three indications. Although the company appears to be trading at ...
Message Board Posts | Cogent Biosciences (NASDAQ:UMRX)
Subject | By | Source | When |
---|---|---|---|
$UMRX / #UNUM Therapeutics Potential 25% Upside | TFMG | investorshub | 08/25/2020 2:09:49 PM |
Do not* | byrdiesoccer | investorshub | 07/28/2020 3:03:52 AM |
Do waste your time with that poster. Venrock | byrdiesoccer | investorshub | 07/28/2020 2:50:58 AM |
Tell that to all the new major fund | cjstocksup | investorshub | 07/27/2020 6:14:22 PM |
Now you may ride it all the way | surf1944 | investorshub | 07/27/2020 4:34:28 PM |
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass. and BOULDER, Colo., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced Andrew Robbins, Chief Executive Officer and President, wil...
Unum Therapeutics Announces Company Name Change to Cogent Biosciences, Highlights Recent Scientific and Operational Progress Cogent Biosciences is focused on the design of rational precision therapies to improve the lives of patients Company on track to advance CGT9486 into ...
SOTIO will establish a T cell therapy R&D Center of Excellence in Cambridge, Massachusetts Unum’s former chief technology officer Geoff Hodge to join SOTIO to lead BOXR development team and all research and development of the next generation T cell therapies Lead progra...